# Modeling lifetime valuelifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → for a prescription brand
A patient starts a biologic for rheumatoid arthritis in January. By month six, roughly a third of similar patients have stopped filling their prescription, not because the drug failed, but because they missed a refill window, hit a prior authorization snag, or got discouraged by an injection site reaction. That drop-off, not a subscription cancel button, is what determines whether this brand is a commercial success. If you model lifetime valuelifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → (LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition →, the total value a patient generates over their treatment relationship with a brand) using SaaS-style logic, you will be wrong, often by a factor of two or more.
This lesson builds an LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → model that reflects how chronic therapy actually behaves: persistence curves, refill cycles, and patient support program (PSP, a manufacturer-run service offering nurse support, co-pay assistance, and adherence coaching) retention data.
The standard formula most marketers learn is:
LTV = Average Revenue per User × Gross Margin % × Average Customer Lifespan
This assumes a smooth, exponential churn curve, the kind you see in streaming or software. Pharma doesn't work that way for three reasons.
Persistence isn't churn. In pharma, "persistence" describes whether a patient continues therapy over time, and it declines in sharp steps tied to clinical events (a specialist visit, a lab result, a side effect), not a steady monthly probability.
Revenue isn't linear per period. A patient on a specialty injectable might refill every 28 days, but a patient on an oral once-daily therapy refills every 90 days through mail order. Revenue timing follows the refill cycle, not a uniform monthly subscription charge.
Retention is engineered, not organic. PSPs actively intervene to keep patients on therapy. This means retention is partly a controllable marketing investment, not a fixed behavioral parameter you simply forecast.
Persistence data usually comes from pharmacy claims databases (e.g., IQVIA or Symphony Health longitudinal prescription data) and is reported as a Kaplan-Meier curve, showing the percentage of patients still on therapy at each time point.
Typical benchmarks for chronic self-injectable therapies (as of 2024 to 2025, estimates, vary widely by disease state):
Oral chronic medications for conditions like hypertension or hyperlipidemia often show *lower* long-term persistence (some published US studies cite under 50% at one year) despite being easier to take, because the perceived stakes feel lower to patients.
Instead of a single "average lifespan," you model time-bucketed survival:
| Month | % patients still on therapy (illustrative) |
|---|---|
| 0 | 100% |
| 3 | 78% |
| 6 | 65% |
| 12 | 52% |
| 24 | 34% |
Revenue to the brand (or net revenue to the manufacturer, after rebates and discounts negotiated with pharmacy benefit managers, PBMs) hits at each refill, not continuously. For a monthly-refill specialty biologic with net revenue of $1,800 per fill (illustrative, post-rebate estimate, actual net prices are confidential and vary hugely by payer contract), you multiply revenue by the probability the patient is still persistent at each fill point.
Simplified worked example:
Assume:
LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → over 12 months ≈ sum of (monthly net revenue × persistence probability at that month)
Rough calculation using the curve above, sampling monthly:
12-month LTV ≈ $14,900 (illustrative, before accounting for gross-to-net adjustments, co-pay assistance costs, or PSP program costs)
Compare this to the naive formula: $1,800 × 12 months = $21,600, assuming full persistence. That's a 31% overstatement, enough to blow an acquisition budget if your cost per patient assumes the higher number.
This is where pharma LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → modeling diverges most from other industries. PSPs directly move the persistence curve. Manufacturers report (in aggregate, non-patient-level terms) that enrolled patients often show meaningfully higher persistence than non-enrolled patients on the same drug, sometimes cited as a 10 to 20 percentage point improvement at 12 months (estimate, varies by program design and disease state).
That means PSP cost is not overhead, it's a lifetime valuelifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → lever, and it belongs in your customer acquisition costcustomer acquisition costCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition → (CACCACCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition →) and marketing math together.
A simplified sensitivity view:
Baseline 12-mo persistence: 52% → LTV ≈ $14,900
With PSP (+15 pts avg persistence): 62% → LTV ≈ $17,600 (illustrative)
PSP cost per enrolled patient (estimate): $600–$1,200/year
Incremental LTV from PSP: ~$2,700If PSP costs $900 per patient and generates ~$2,700 in incremental LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition →, that's a marketing investment with a clear, calculable return, the kind of case you'd build for a brand team or a pharmacy access committee.
For real-world persistence and adherence methodology, the CDC's guidance on medication adherence measures and published claims-based persistence studies in journals indexed on PubMed are solid starting references.
Knowledge check
1. Why does applying the standard SaaS LTV formula (ARPU × Gross Margin % × Average Lifespan) to a prescription brand tend to produce significantly inaccurate results?
2. A patient stops filling their biologic prescription after a prior authorization snag, even though the drug is working well clinically. How should this be understood in the context of pharma LTV modeling?
3. Why is revenue timing for prescription brands not well-represented by a uniform monthly subscription charge?
4. Select ALL correct answers about why treating patient retention as a fixed, forecastable parameter is a mistake when modeling pharma LTV.
Select all the correct answers.
5. Select ALL correct answers about how 'persistence' differs from 'churn' as typically modeled in subscription businesses.
Select all the correct answers.
Net revenue per fill is never the list price. Gross-to-net (GTN) describes the erosion from wholesale acquisition costacquisition costCustomer Acquisition Cost (CAC) is the total sales and marketing spend divided by the number of new customers gained in a period. It measures how efficiently you grow.View full definition → (WAC) down to what the manufacturer actually keeps, after rebates to PBMs, discounts to payers, co-pay assistance, and distribution fees. In the US, GTN erosion for branded specialty drugs commonly runs 40% to 50% or more off list price (widely cited industry estimate, varies significantly by therapeutic class and negotiating leverage).
In Europe, the picture is different: most markets use direct price negotiation or reference pricing with national health systems (e.g., Germany's AMNOG process, France's CEPS negotiations), so "net price" is often set upfront rather than eroded through rebates. This means European LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → models usually have less month-to-month revenue volatility but lower absolute per-patient revenue than the US.
Always model LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → on net, not list, price. Using WAC will inflate every number in this lesson substantially.
$$
LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → = \sum_{t=1}^{T} (\text{Net Revenue per Fill}_t \times \text{Persistence}_t) - \text{PSP and Access Support Costs}
$$
Where persistence is drawn from real claims data or clinical trial extension studies, not assumed to decay smoothly, and PSP costs are treated as an LTVLTVLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition →-improving investment, not a sunk marketing expense.
🎬 [VIDEO: "How Pharma Companies Use Real-World Data" - youtube.com - search for IQVIA or Definitive Healthcare explainer content on claims-based patient journey analytics, illustrating how persistence data is sourced in practice]